A phase 3 clinical trial (NSABP B-35 (NCT00053898)) has found that margin widths of 1 mm vs 2 mm after lumpectomy in postmenopausal women with estrogen receptor–positive (ER+) DCIS do not result in clinically meaningful differences in rates of ipsilateral breast tumor recurrence (IBTR). The findings were presented at the American Society of Breast Surgeons conference by Dr. Irene Wapnir of Stanford Medicine.
The trial included over 3,100 postmenopausal women with ER+ DCIS, all of whom received whole-breast irradiation and 5 years of hormone therapy (tamoxifen or anastrozole) after lumpectomy. Looking at 10-year rates of IBTR, the study found that rates were similar regardless of whether surgical margins were <1 mm or ≥1 mm, and likewise for <2 mm vs ≥2 mm. No significant differences were found between treatment arms using tamoxifen vs anastrozole.
These results suggest that re-excision for margin widths less than 1–2 mm may not be necessary, which could reduce unnecessary surgeries.
For more information about this study, click here.
No Comments
No comments yet.
RSS feed for comments on this post. TrackBack URL
Sorry, the comment form is closed at this time.